Collaboration on Analysing Dendrimers for Diagnostics

 
Post new topic   Reply to topic    Institute of Nanotechnology Forum Index -> Nanobiomed
View previous topic :: View next topic  
Author Message
grantnano
Site Admin


Joined: 03 Oct 2005
Posts: 432

PostPosted: Thu Oct 20, 2005 1:02 pm    Post subject: Collaboration on Analysing Dendrimers for Diagnostics Reply with quote

Dendritic Nanotechnologies and Nanotechnology Characterization Laboratory Announce Collaboration on Analysing Dendrimers for Medical Diagnostics

Nanotechnology Characterization Laboratory (NCL), a company that is focused on the discovery, development, and commercialization of dendrimer technologies to create a new generation of innovative products for the identification and treatment of human diseases, has entered into one of the first characterization collaborations with the Nanotechnology Characterization Laboratory (NCL), an organization established by the National Cancer Institute to foster collaboration between the government and the private sector. The agreement with NCL will focus on the characterization by NCL of DNT's STARBURST TM dendrimers as macromolecular dendrimer-based MRI contrast agents for sensitive, non-invasive cardiovascular diagnostics.

DNT's STARBURST and Priostar TM dendrimers are "smart" biopharmaceutical nanotechnology platforms that can be used to deliver precise quantities of a drug or contrast agent to a specific location within the human body. DNT's dendrimers will be subjected to an assay cascade consisting of physical characterization, in vitro studies, and in vivo ADME/Tox protocols to determine their absorption, distribution, metabolism, excretion, and toxicity. DNT's proprietary dendrimer platform also serves as a targeted diagnostic and therapeutic delivery system for a wide variety of drugs to cancer cells and other diseases. Improved efficacy, enhanced solubility, and lower toxicity have been demonstrated for many existing drugs.

The intent of these studies is to generate data in support of an investigative new drug ( IND) filing with the U.S. Food and Drug Agency (FDA). It is estimated that the NCL's characterization efforts will take approximately 12-15 months.

"Development of dendrimer-based MRI contrast agents for sensitive, non- invasive intravascular agents is highly desired in the medical world," said Robert Berry, DNT's chief executive officer. "DNT's STARBURST dendrimers have demonstrated intravascular properties that increase sensitivity and image clarity with potentially lower dosage compared to currently available general-use contrast agents. DNT's smart nanostructures feature precise and predictable physical properties that make them especially useful in commercial applications requiring novel properties with nanometer precision."

The collaboration agreement with DNT is one of the first characterization agreements entered into by the NCL and will be used to perform a preclinical assessment of DNT's intravascular dendrimer-based MRI contrast agents. These assessments will help provide the data necessary to enter the FDA's Phase I clinical trials. This will be the second dendrimer-based application submitted to FDA: Starpharma Holdings Ltd. (a DNT license holder and investor) is currently entering Phase II clinical trials with a dendrimer-based topical microbicide, VivaGel TM, aimed at the prevention of HIV.

In 2005, the National Institute of Standards and Technology, the Food and Drug Administration, and the National Cancer Institute established the Nanotechnology Characterization Laboratory to perform preclinical efficacy and toxicity testing of nanoscale materials. A key activity of the NCL will be to work with FDA scientists to develop an assay cascade that can serve as the standard protocol for preclinical toxicology, pharmacology, and efficacy of nanoscale materials. This assay cascade will characterize a nanoscale device's physical attributes, its in vitro biological properties, and its in vivo compatibility.

Dendrimers - an Emerging Platform for New Diagnostics
The versatility of the dendrimer architecture provides DNT and its commercial partners with unique advantages. The ability to control the properties of size, surface, and encapsulation are critical to any intravascular agent product. Feasibility studies on dendrimer-based contrast agents have demonstrated excellent carrying capacity, superior image enhancement, and sufficient retention for imaging, with good routes of elimination. The use of dendrimers as a platform for new therapies has already yielded excellent results: DNT has encapsulated Magnevist®, AG Schering's off-patent, low molecular weight, market-leading contrast agent, within its STARBURST and Priostar dendrimers. DNT's technology has allowed Magnevist molecules to be contained within the dendrimer interior, resulting in the creation of a macromolecular contrast agent with the surface available for further modification.

About the Nanotechnology Characterization Laboratory
The Nanotechnology Characterization Laboratory (NCL) performs and standardizes the pre-clinical characterization of nanomaterials intended for cancer therapeutics and diagnostics developed by researchers from academia, government, and industry. The NCL serves as a national resource and knowledge base for cancer researchers, and facilitates the development and translation of nanoscale particles and devices for clinical applications.

The National Cancer Institute believes that the NCL's activities will markedly speed the development of nanotechnology-based products for cancer patients, reduce the risk of doing so, and encourage private-sector investment in this promising area of technology development. By achieving its goals, the NCL will provide a comprehensive set of baseline characterization parameters that will enable cancer biologists, drug and diagnostic developers, and clinical oncologists to apply their tools to solving problems that most affect cancer patients. This work will also lay a scientific foundation that will enable the FDA to make sound decisions concerning the testing and approval of nanoscale cancer diagnostics, imaging agents, and therapeutics.

Source: Dendritic Nanotechnologies.

URL: http://dnanotech.com/news_detail.php?id=16
Back to top
View user's profile Send private message
Display posts from previous:   
Post new topic   Reply to topic    Institute of Nanotechnology Forum Index -> Nanobiomed All times are GMT
Page 1 of 1
 

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum


Powered by phpBB © 2001, 2002 phpBB Group